IDH2 and acute myeloid leukemia: In a phase I trial, the oral IDH2 inhibitor AG-221 induced an overall response rate of 62.5% and a complete response rate of 37.5% in patients with relapsed or refractory IDH2-mutated AML and MDS [27].